Ignite Creation Date:
2025-12-25 @ 4:53 AM
Ignite Modification Date:
2025-12-26 @ 3:54 AM
Study NCT ID:
NCT07275918
Status:
RECRUITING
Last Update Posted:
2025-12-10
First Post:
2025-11-19
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
SA1211 Injection Phase 1 Study
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D019694', 'term': 'Hepatitis B, Chronic'}], 'ancestors': [{'id': 'D006509', 'term': 'Hepatitis B'}, {'id': 'D000086982', 'term': 'Blood-Borne Infections'}, {'id': 'D003141', 'term': 'Communicable Diseases'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D018347', 'term': 'Hepadnaviridae Infections'}, {'id': 'D004266', 'term': 'DNA Virus Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D006525', 'term': 'Hepatitis, Viral, Human'}, {'id': 'D006521', 'term': 'Hepatitis, Chronic'}, {'id': 'D006505', 'term': 'Hepatitis'}, {'id': 'D008107', 'term': 'Liver Diseases'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D002908', 'term': 'Chronic Disease'}, {'id': 'D020969', 'term': 'Disease Attributes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SEQUENTIAL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 80}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2025-11-25', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-12', 'completionDateStruct': {'date': '2027-03-30', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-12-08', 'studyFirstSubmitDate': '2025-11-19', 'studyFirstSubmitQcDate': '2025-12-08', 'lastUpdatePostDateStruct': {'date': '2025-12-10', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2025-12-10', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2027-03-30', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of participants with AEs, SAEs and abnormal laboratory testings', 'timeFrame': 'Approximate 24 weeks', 'description': 'AEs: Adverse Events. SAEs: Serious Adverse Events.'}], 'secondaryOutcomes': [{'measure': 'Cmax: maximum concentration', 'timeFrame': 'Pre-dose, multiple time-points post dose until 48 hours'}, {'measure': 'Tmax', 'timeFrame': 'Pre-dose, multiple time-points post dose until 48 hours', 'description': 'Tmax: Time to Maximum Concentration'}, {'measure': 'AUC0-t', 'timeFrame': 'Pre-dose, multiple time-points post dose until 48 hours', 'description': 'AUC0-t: Area Under the Concentration-Time Curve from Time Zero to the Last Quantifiable Concentration'}, {'measure': 'AUC0-inf', 'timeFrame': 'Pre-dose, multiple time-points post dose until 48 hours', 'description': 'AUC0-inf: Area Under the Concentration-Time Curve from Time Zero to Infinity'}, {'measure': 't1/2', 'timeFrame': 'Pre-dose, multiple time-points post dose until 48 hours', 'description': 't1/2: Half-life'}, {'measure': 'λz', 'timeFrame': 'Pre-dose, multiple time-points post dose until 48 hours', 'description': 'λz: Terminal Elimination Rate Constant'}, {'measure': 'Vd/F', 'timeFrame': 'Pre-dose, multiple time-points post dose until 48 hours', 'description': 'Vd/F: Volume of Distribution over Bioavailability'}, {'measure': 'CL/F', 'timeFrame': 'Pre-dose, multiple time-points post dose until 48 hours', 'description': 'CL/F: Clearance over Bioavailability'}, {'measure': 'Css (Steady-State Concentration)', 'timeFrame': 'Pre-dose, multiple time-points post dose until 48 hours'}, {'measure': 'DF (Degree of Fluctuation)', 'timeFrame': 'Pre-dose, multiple time-points post dose until 48 hours'}, {'measure': 'The number of participants with chronic hepatitis B (CHB) who achieved hepatitis B surface antigen (HBsAg) clearance', 'timeFrame': 'Approximate 24 weeks'}, {'measure': 'Maximum HBsAg Decline in CHB Participants Within 24 Weeks (log10)', 'timeFrame': 'Approximate 24 weeks'}, {'measure': 'The number of CHB Participants with HBsAg Seroconversion at each assessment time Point within 24 weeks', 'timeFrame': 'Approximate 24 weeks'}, {'measure': 'The number of CHB participants who achieved HBeAg seronegativity at each assessment time point within 24 weeks', 'timeFrame': 'Approximate 24 weeks'}, {'measure': 'The number of participants with immunogenicity (i.e., anti-drug antibodies [ADAs])', 'timeFrame': 'Approximate 24 weeks'}, {'measure': 'The change in QTcF relative to baseline and the change relative to placebo', 'timeFrame': 'Approximate 24 weeks', 'description': 'Apply for healthy participants'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['CHB'], 'conditions': ['Chronic Hepatitis B']}, 'descriptionModule': {'briefSummary': 'The goal of this clinical trial is to evaluate the safety, tolerability, immunogenicity and Pharmacokinetics (PK) characteristics of SA1211 Injection in healthy volunteers (Part A) and participants with chronic hepatitis B (CHB, Part B), and assess its preliminary efficacy in participants with chronic hepatitis B (CHB). The main questions it aims to answer are:\n\nWhat are the safety, tolerability, immunogenicity and PK characteristics of a single subcutaneous injection of SA1211 Injection in healthy volunteers (Part A)? What are the safety, tolerability, immunogenicity and PK characteristics of multiple subcutaneous injections of SA1211 Injection in participants with CHB (Part B)? What is the preliminary efficacy of SA1211 Injection in participants with CHB (Part B)?\n\nParticipants will:\n\n* Part A (healthy volunteers): Receive a single subcutaneous injection of SA1211 Injection or placebo and complete relevant safety, tolerability and PK monitoring as required.\n* Part B (participants with CHB): Receive multiple subcutaneous injections of SA1211 Injection or placebo and complete relevant safety, tolerability, PK monitoring and preliminary efficacy assessment as required.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Able to correctly understand and sign the informed consent form in writing.\n2. Male or female participants.\n\n * For healthy participants: aged 18-55 years old (inclusive of the cut-off values).\n * For participants with chronic hepatitis B (CHB): aged 18-65 years old (inclusive of the cut-off values).\n3. Body Mass Index (BMI) meets the following requirements.\n\n * For healthy participants: within the range of 18-28 kg/m² (inclusive of the cut-off values).\n * For participants with chronic hepatitis B (CHB): within the range of 18-32 kg/m² (inclusive of the cut-off values).\n4. During the screening period, the results of the following examinations are either normal or abnormal but not clinically insignificant:\n\n \\- Clinical laboratory tests: complete blood count, blood biochemistry, coagulation function, urine routine. Thyroid function test. 12-lead electrocardiogram (ECG). Abdominal ultrasound. Posteroanterior chest X-ray.\n5. For participants with chronic hepatitis B (CHB): documented hepatitis B virus (HBV) infection for at least 6 months before screening, with positive hepatitis B surface antigen (HBsAg) and/or positive HBV deoxyribonucleic acid (HBV DNA).\n6. For female participants of childbearing potential: must not be pregnant or lactating, and agree to use effective contraception during the study period.\n7. For male participants of childbearing potential: agree to use effective contraception during the study period to ensure effective contraception for their sexual partners.\n\nExclusion Criteria:\n\n1. Participants with concurrent hepatitis C virus (HCV), human immunodeficiency virus (HIV) or syphilis infection; or those previously diagnosed with hepatitis A, D, or E who have not been cured.\n2. Participants with severe diseases, including but not limited to diseases of the nervous, cardiovascular, hematological and lymphatic, immune, renal, hepatic, thyroid, gastrointestinal, respiratory, metabolic, and skeletal systems, as well as a history of malignant tumors.\n3. Participants with severe mental illness or uncontrolled mental disorders, including but not limited to schizophrenia, bipolar disorder, or depression.\n4. Participants with a systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg at screening, who are deemed unsuitable for the study by the investigator.\n5. Participants who have undergone major surgery within 6 months before screening, or plan to undergo surgery during the study period.\n6. Participants with severe infection or trauma within 4 weeks before screening.\n7. Participants with a severe allergic constitution, or a confirmed allergy to this product or its formulation components.\n8. Participants who smoked more than 5 cigarettes per day or the equivalent amount of tobacco within 3 months before screening.\n9. Participants deemed unsuitable for the trial by the investigator due to other factors.'}, 'identificationModule': {'nctId': 'NCT07275918', 'briefTitle': 'SA1211 Injection Phase 1 Study', 'organization': {'class': 'INDUSTRY', 'fullName': 'Suzhou Siran Biotechnology Co.,Ltd.'}, 'officialTitle': 'A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SA1211 Injection in Healthy Participants and Participants With Chronic Hepatitis B', 'orgStudyIdInfo': {'id': 'SAHB101'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Healthy Participants', 'interventionNames': ['Drug: SA1211 injection', 'Drug: SA1211 injection placebo']}, {'type': 'EXPERIMENTAL', 'label': 'Chronic Hepatitis B', 'interventionNames': ['Drug: SA1211 injection', 'Drug: SA1211 injection placebo']}], 'interventions': [{'name': 'SA1211 injection', 'type': 'DRUG', 'description': 'subcutaneous injection', 'armGroupLabels': ['Chronic Hepatitis B', 'Healthy Participants']}, {'name': 'SA1211 injection placebo', 'type': 'DRUG', 'description': 'subcutaneous injection', 'armGroupLabels': ['Chronic Hepatitis B', 'Healthy Participants']}]}, 'contactsLocationsModule': {'locations': [{'zip': '130031', 'city': 'Changchun', 'state': 'Jilin', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Yanhua Ding', 'role': 'CONTACT', 'email': 'dingyanhua2003@126.com', 'phone': '+86 0431-85612345'}, {'name': 'Junqi Niu', 'role': 'CONTACT', 'email': 'junqiniu@aliyun.com'}, {'name': 'Yanhua Ding, PhD.', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Junqi Niu, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'The First Hospital of Jilin University', 'geoPoint': {'lat': 43.88, 'lon': 125.32278}}], 'centralContacts': [{'name': 'Feifei Zhao', 'role': 'CONTACT', 'email': 'zhaofeifei@siranbio.com', 'phone': '+86 0512-65295926'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Suzhou Siran Biotechnology Co.,Ltd.', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'Beijing Siran Biotechnology Co.,Ltd.', 'class': 'UNKNOWN'}], 'responsibleParty': {'type': 'SPONSOR'}}}}